Bayer's Pharma Momentum Meets Its Day of Reckoning in Missouri

Bayer shares fell 2.3% to EUR 47.96 as investors await a Missouri court ruling on its proposed $7.25 billion Roundup settlement despite two new FDA approvals.

Bayer shares slipped 2.3% on Friday to close at EUR 47.96, a modest pullback that nonetheless lands at an awkward intersection: the German group's pharmaceutical arm is delivering regulatory wins at pace, while its legal legacy in the United States still awaits a single, decisive signature from a state judge.

The stock has climbed 30% since the start of the year, yet it now trades just below its 50-day moving average of EUR 48.39 — a technical line that has become a proxy for whether the market believes the pharma story can outrun the glyphosate overhang.

Two FDA Approvals, One Unresolved Question

September brought a pair of significant US regulatory green lights. Sevabertinib secured accelerated approval as a first-line therapy for certain forms of lung cancer, while Kerendia — known chemically as finerenone — won an expanded indication for chronic kidney disease in adults with type 1 diabetes, targeting a reduction in albuminuria.

The Kerendia label extension rests on data from the Phase III FINE-ONE trial, which enrolled 242 patients over six months. The drug cut the urine albumin-to-creatinine ratio by 34%, against 12% for placebo — a 25-percentage-point edge over the dummy treatment. Safety data showed hyperkalemia in 10.1% of participants versus 3.3% on placebo, though therapy-related discontinuations stayed low at 1.7%.

It marks the first new treatment option for chronic kidney disease in type 1 diabetes in three decades, and Bayer has guided toward peak annual sales exceeding EUR 3 billion for the drug. That figure matters because the company needs fresh revenue streams to offset patent expiries on older medicines. Group revenue in the second quarter of 2026 came in at EUR 10.87 billion, only modestly ahead of the prior-year EUR 10.74 billion.

Sevabertinib's accelerated pathway, meanwhile, carries its own strings: continued approval hinges on confirmatory clinical data. Should follow-up studies disappoint, the drug's addressable patient population could narrow.

The $7.25 Billion Question

None of that will fully register with institutional investors until the legal picture clears. A proposed $7.25 billion Roundup settlement went before a Missouri court last Monday, and market participants are now waiting for the formal ruling.

The Eighth Circuit Court of Appeals in late August rejected an attempt by plaintiffs to move the proceedings to a federal venue, leaving jurisdiction in Missouri intact. That decision kept the case on state turf — precisely where Bayer needs approval to consolidate a meaningful share of the outstanding litigation and shield itself from unpredictable jury verdicts.

There is a supportive precedent: the US Supreme Court ruled 7-2 in the Durnell case that federal FIFRA provisions preempt state-level failure-to-warn claims where the EPA has confirmed product safety. But translating that principle into courtroom practice still requires the settlement to be ratified at the state level.

If the Missouri court withholds approval, or attaches fresh conditions, the Leverkusen-based group faces an extended stretch of uncertainty. The legal question is currently overshadowing valuation multiples, as fund managers demand a reliable ceiling on remaining litigation costs before pricing in operational growth.

What Approval Would Unlock

A prompt green light, combined with the Supreme Court precedent, would strip the legal basis from much of the remaining wave of claims. The removal of that valuation discount would open room for a broader re-rating of the equity.

On that cleaner footing, the pharma division's earnings power could come to the fore. Kerendia and sevabertinib together — one in nephrology, one in oncology — could offset the revenue erosion from older drugs losing patent protection. The company would then be supported from two directions: a falling risk premium on agricultural liabilities, and rising expected cash flows from oncology and nephrology.

The Risks That Could Derail the Recovery

The most obvious downside scenario is rejection or substantial delay in Missouri. If the court demands renegotiation or sides with objecting plaintiff groups, the $7.25 billion figure would be back on the table. A higher settlement would weigh further on the balance sheet and slow deleveraging.

Commercial execution carries its own hazards. Kerendia's uptake depends on reimbursement decisions from health insurers, and the need for regular potassium monitoring may make some physicians hesitant to start therapy early. In the US, drug-pricing initiatives advanced under the Inflation Reduction Act are adding pressure on reimbursement rates for modern therapies; restrictive formulary placement could leave sales growth short of expectations.

Should legal setbacks coincide with a slow revenue ramp for the new medicines, the stock would struggle to defend its year-to-date gains. The market would refocus on legacy liabilities rather than future earnings prospects.

The Catalysts Ahead

Two dates now frame the near-term outlook. The Missouri Circuit Court's ruling on the settlement is expected soon after last week's hearing. Then, on 3 November 2026, Bayer publishes its interim report for the third quarter.

That report will show how much of the pharma momentum is flowing through to the numbers, and whether full-year targets remain on track. Until then, market watchers are likely to focus on early signals of Kerendia's US prescription trend.

For the chart to stay constructive, the stock needs to hold the EUR 48.39 area around its 50-day moving average. A sustained break below that level would risk a consolidation phase in which broader skepticism toward the agriculture and pharmaceutical sectors regains the upper hand — and the distance to the 52-week high of EUR 53.86 would widen further.